Evaluation of a Recombinant Antigen-Based Enzyme Immunoassay for the Diagnosis of Noninvasive Aspergillosis
- 1 March 2012
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 50 (3) , 762-765
Abstract
Antibody detection is a key diagnostic tool for noninvasive aspergillosis (NIA) such as allergic bronchopulmonary aspergillosis and chronic pulmonary aspergillosis. Specific immunoprecipitin detection (IPD) is considered as the reference but lacks standardization and is time-consuming. To evaluate the performance of a new anti- Aspergillus fumigatus IgG enzyme immunoassay (EIA) kit using a recombinant A. fumigatus antigen (Bio-Rad), a retrospective study was performed on 551 sera collected from patients with a definite diagnosis of NIA (group 1; n = 64), bronchial Aspergillus colonization (group 2; n = 26), and probable aerial Aspergillus contamination (group 3; n = 44); from patients suspected of NIA with negative serological and mycological investigations (group 4; n = 49); and from a group of 222 patients not suspected of NIA (group 5). The EIA exhibited excellent reproducibility with coefficients of variation below 10%. Agreement with IPD was calculated between 62.5 and 84.4% according to the group of patients with Cohen's kappa coefficient at 0.6196 ± 0.077. Taking as reference a composite status including clinical, radiological, mycological, and serological data, sensitivity (group 1) and specificity (other groups) were calculated between 90.2 and 93.8% and 54.3 and 100%, respectively. Lower specificity was observed for patients with Aspergillus colonization. However, Yule Q coefficients estimating the correlation between EIA result and the definite diagnosis of NIA were calculated between 0.97 and 0.98. The method is a highly useful screening tool for the diagnosis of NIA, reducing the need for confirmatory IPD tests.Keywords
This publication has 18 references indexed in Scilit:
- Aspergillus fumigatus colonization in cystic fibrosis: implications for lung function?Clinical Microbiology and Infection, 2011
- Efficacy and Safety of Posaconazole for Chronic Pulmonary AspergillosisClinical Infectious Diseases, 2010
- Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosisCurrent Opinion in Pulmonary Medicine, 2010
- Chronic Cavitary and Fibrosing Pulmonary and Pleural Aspergillosis: Case Series, Proposed Nomenclature Change, and ReviewClinical Infectious Diseases, 2003
- Significance of Aspergillus fumigatus Isolation from Respiratory Specimens of Nongranulocytopenic PatientsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Use of Recombinant Mitogillin for Improved Serodiagnosis ofAspergillus fumigatus-Associated DiseasesJournal of Clinical Microbiology, 2001
- Automated specific IgE assay with recombinant allergens: evaluation of the recombinant Aspergillus fumigatus allergen I in the Pharmacia CAP SystemClinical & Experimental Allergy, 1996
- Identification of Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients by Recombinant Aspergillus Fumigatus I/A-Specific SerologyAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Serum anti-Aspergillus fumigatus antibodies by immunoblot and ELISA in cystic fibrosis with allergic bronchopulmonary aspergillosisJournal of Allergy and Clinical Immunology, 1994
- Antibodies against Aspergillus fumigatusInternational Archives of Allergy and Immunology, 1980